X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.fiercepharma.com/pharma/fda-moves-takedas-iclusig-first-line-use-rare-philadelphia-chromosome-all
https://www.onclive.com/view/ponatinib-plus-low-dose-chemotherapy-improves-mrd-cr-rates-in-newly-diagnosed-ph-all
https://www.fiercepharma.com/pharma/asco-takedas-iclusig-shows-potential-become-soc-phall
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-ponatinib-hydrochloride-56531.pdf
https://www.businesswire.com/news/home/20221117005280/en/Phase-3-Trial-of-ICLUSIG%C2%AE-ponatinib-Met-Primary-Endpoint-in-Newly-Diagnosed-Ph-ALL-a-Setting-with-No-Targeted-Treatments-Approved-in-the-US
https://www.cancernetwork.com/view/fda-approves-ponatinib-to-treat-adult-patients-with-resistant-intolerant-chronic-phase-cml
https://www.cancernetwork.com/view/fda-approves-ponatinib-to-treat-adult-patients-with-resistant-intolerant-chronic-phase-cml
https://www.takeda.com/newsroom/newsreleases/2020/takeda-to-present-data-from-the-iclusig-ponatinib-clinical-trial-program-that-could-prove-practice-changing-for-the-treatment-of-chronic-phase-cml/
https://www.prnewswire.com/news-releases/marker-therapeutics-reports-interim-results-of-its-multitaa-specific-t-cell-therapy-in-patients-with-pancreatic-adenocarcinoma-at-the-2020-american-society-of-clinical-oncology-asco-virtual-annual-meeting-301067451.html
https://www.gov.uk/drug-safety-update/ponatinib-iclusig-reports-of-posterior-reversible-encephalopathy-syndrome
https://www.gov.uk/drug-safety-update/ponatinib-iclusig-reports-of-posterior-reversible-encephalopathy-syndrome
https://www.gov.uk/drug-safety-update/ponatinib-iclusig-reports-of-posterior-reversible-encephalopathy-syndrome
https://www.ema.europa.eu/documents/procedural-steps-after/iclusig-epar-procedural-steps-taken-scientific-information-after-authorisation_en-0.pdf
https://www.ema.europa.eu/documents/scientific-conclusion/iclusig-h-c-psusa-00010128-201712-epar-scientific-conclusions-grounds-variation-terms-marketing_en.pdf
https://www.fiercebiotech.com/biotech/f-prime-atlas-lead-cancer-startup-akrevia-to-30m-a-round
https://www.businesswire.com/news/home/20180322005194/en/Takeda-Announces-Publication-Final-Data-ICLUSIG%C2%AE-ponatinib
https://www.businesswire.com/news/home/20180322005194/en/Takeda-Announces-Publication-Final-Data-ICLUSIG%C2%AE-ponatinib
http://www.biospace.com/News/biotech-startup-prelude-therapeutics-gets-grant-to/466484/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.pharmatimes.com/news/nice_backs_routine_use_of_incytes_leukaemia_drug_1186477
http://www.biospace.com/News/ariad-stays-mum-on-layoffs-after-takedas-5-2/445200/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.biospace.com/News/a-peek-behind-the-curtain-of-the-ariad-takeda-deal/444657/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.forbes.com/sites/matthewherper/2017/01/09/staggering-drug-price-increases-result-in-5-billion-payday-for-ariad-pharmaceuticals/#50915ceb504d
http://www.fiercepharma.com/pharma/takeda-shells-out-whopping-5-2b-for-ariad-iclusig-and-its-fledgling-med-brigatinib
https://www.statnews.com/pharmalot/2016/10/20/bernie-sanders-ariad-cancer-drug-data/
http://www.biospace.com/News/why-incyte-biogen-and-biomarin-are-hot-acquisition/435419/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-eng.php
http://twofourinsight.com/health-canadarequires-warning-gleevec-labeling-brand-generics/
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-eng.php
http://www.fiercepharma.com/story/can-baxalta-hold-shire-its-own-bid-ariad/2015-08-31
http://www.pharmatimes.com/Article/15-04-13/Seven_new_drugs_OK_d_for_NHS_Scotland.aspx
http://www.fiercepharma.com/story/activists-ready-fight-ariad-ceos-ouster-cnbc/2015-02-13
Market Place
Share 
